A Risk Management Approach to Global Pandemics of Infectious Disease and Anti-Microbial Resistance
Abstract
:Highlights
- All polioviruses are polio. Whether wild or vaccine-derived, they spread invisibly and paralyze the same way. The single-disease approach to polio and exclusive focus on vaccination without chlorination of drinking water has facilitated poliovirus’ survival and driven vaccine-derived variants. Poliovirus is now circulating on 5 continents. Reliance on laboratory diagnosis for surveillance and treatment enables polio, tuberculosis, and other diseases which spread invisibly, to flourish.
- Attacks on healthcare, an increasingly popular war strategy, include destroying public health and withholding chlorine, and are designed to drive disease and fuel anti-microbial resistance (AMR). Polio outbreaks in conflict zones are not a by-product of war but are a form of biological warfare and the result of weaponizing healthcare.
- To achieve a world where polio is no longer a threat, the Global Polio Eradication Initiative must stop chasing the virus and focus on ending the disease. Since poliovirus is waterborne and inactivated by chlorine, which kills 99.9% of microbes, chlorination of drinking water should be prioritized. This is a logical and crucial investment to supplement vaccination and curb vaccine-derived polio, increase immunogenicity by controlling other water-borne viruses, and reduce our reliance on antibiotics.
- The World Health Organization must recognize that disease and permanently infected wounds are the object of attacking healthcare and withholding aid, not the unfortunate outcome. It must define attacks on healthcare in a way that enables the attribution of responsibility and the prosecution of these war crimes, which are a threat to global security.
Abstract
1. Introduction
2. The Global Polio Eradication Initiative
2.1. Vaccine-Derived Polio
2.2. Chlorine as a Primary Tool of Public Health
3. Conflict as a Driver of Infectious Disease and AMR
3.1. Attacks on Healthcare
Surveillance System of Attacks on Healthcare WHO (WHO-SSA)
- Systematic collection of evidence of attacks,
- Advocacy for the end of such attacks, and
- The promotion of good practices for protecting healthcare from attacks.
3.2. Conflict and Polio
3.2.1. Conflict and cVDPV
3.2.2. Immunogenicity, Vaccine Efficacy, and Herd Immunity
3.3. Democratic Republic of Congo
3.4. Conflict, Contagious Diseases, and AMR—The New Biological Warfare
3.4.1. Landmines
3.4.2. Attacks on Healthcare and AMR: Targeting Healthcare and Public Health
3.4.3. Acinetobacter baumannii (Iraqibacter)
3.5. Conflict and AMR: Tuberculosis
3.6. The Impact of Conflict on Challenges of Surveillance, Diagnosis and Treatment
4. Next Steps Towards a Host-Strengthening and Holistic Approach to Pandemic Infectious Diseases and AMR
4.1. Chlorination of Drinking Water
4.2. Harnessing the Non-Specific Beneficial Effects of OPV and Other Live Vaccines
4.3. Benefits of OPV Versus IPV
4.4. The Potential of Live Vaccines for Strengthening Host Defenses in Emergency Situations
5. Discussion
5.1. Vaccine Hesitancy and Distrust
5.2. The Biomedical Model Alone Has Failed
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Constitution of the World Health Organization. Available online: https://www.who.int/about/governance/constitution (accessed on 24 October 2024).
- National Research Council (US) Safe Drinking Water Committee. The Disinfection of Drinking Water. In Drinking Water and Health: Volume 2; National Academies Press: Washington, DC, USA, 1980. Available online: https://www.ncbi.nlm.nih.gov/books/NBK234591/ (accessed on 23 October 2024).
- Conroy, J.M.; Conroy, B.B.; Laird, A.T. The Destruction of Tubercle Bacilli in Sewage by Chlorine. Am. Rev. Tuberc. 1922, 6, 63–68. Available online: https://www.atsjournals.org/doi/abs/10.1164/art.1922.6.1.63 (accessed on 23 October 2024).
- World Health Organization. Political Declaration of the High-level Meeting on Antimicrobial Resistance. Available online: https://www.un.org/pga/wp-content/uploads/sites/108/2024/09/FINAL-Text-AMR-to-PGA.pdf (accessed on 4 November 2024).
- Progress Toward Global Poliomyelitis Eradication. 2000. Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5016a5.htm (accessed on 27 October 2024).
- Poliomyelitis. Available online: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis (accessed on 24 September 2024).
- Global Polio Eradication Initiative. GPEI Announces Strategy Extension and Revised Budget to Protect All Children from Polio. Available online: https://polioeradication.org/news/gpei-announces-strategy-extension-and-revised-budget-to-protect-all-children-from-polio/ (accessed on 17 October 2024).
- Global Polio Eradication Initiative. 22nd Report of the Independent Monitoring Board. Available online: https://polioeradication.org/wp-content/uploads/2023/09/22nd-Report-of-The-Independent-Monitoring-Board-IMB.pdf (accessed on 30 September 2024).
- Global Polio Eradication Initiative. The Long Goodbye 23rd Report of the Independent Monitoring Board. Available online: https://polioeradication.org/wp-content/uploads/2024/09/23rd-IMB-Report-20240922.pdf (accessed on 30 September 2024).
- World Health Assembly, 41. Global Eradication of Poliomyelitis by the Year 2000. World Health Organization. 1988. Available online: https://iris.who.int/handle/10665/164531 (accessed on 23 October 2024).
- Smallpox—Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/smallpox/index.html (accessed on 23 October 2024).
- CDC Chapter 18: Poliomyelitis. Available online: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html (accessed on 24 September 2024).
- Tajaldin, B.; Almilaji, K.; Langton, P.; Sparrow, A. Defining Polio: Closing the Gap in Global Surveillance. Ann. Glob. Health 2015, 81, 386–395. [Google Scholar] [CrossRef] [PubMed]
- Chumakov, K.; Ehrenfeld, E.; Agol, V.I.; Wimmer, E. Polio Eradication at the Crossroads. Lancet Glob. Health 2021, 9, e1172–e1175. [Google Scholar] [CrossRef] [PubMed]
- Global Polio Eradication Initiative GPEI-Archived Budgets (2003–2020) July 2013. Available online: https://polioeradication.org/wp-content/uploads/2016/07/FRR2013-2018_July2014_EN_A4.pdf (accessed on 28 September 2024).
- Vaccines Pricing Data|UNICEF Supply Division. Available online: https://www.unicef.org/supply/vaccines-pricing-data (accessed on 28 October 2024).
- Kew, O.; Morris-Glasgow, V.; Landaverde, M.; Burns, C.; Shaw, J.; Garib, Z.; André, J.; Blackman, E.; Freeman, C.J.; Jorba, J.; et al. Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus. Science 2002, 296, 356–359. [Google Scholar] [CrossRef]
- Development of a New Oral Poliovirus Vaccine for the Eradication End Game Using Codon Deoptimization. Available online: https://www.proquest.com/docview/2488773024?accountid=41157&pq-origsite=primo&sourcetype=Scholarly%20Journals (accessed on 22 October 2024).
- Global Polio Eradication Initiative. GPEI-Global Wild Poliovirus and cVDPV 2018–2024. Available online: https://polioeradication.org/circulating-vaccine-derived-poliovirus-count/ (accessed on 24 September 2024).
- Cho, R. Maintaining the Superiority of NYC’s Drinking Water—Columbia Climate School State of the Planet. 2011. Available online: https://news.climate.columbia.edu/2011/07/29/maintaining-the-superiority-of-nyc%E2%80%99s-drinking-water/ (accessed on 3 November 2024).
- Death and the Human Environment: The United States in the 20th Century—The Rockefeller University—Program for the Human Environment. Available online: https://phe.rockefeller.edu/publication/death-human-environment-united-states-20th-century/ (accessed on 24 October 2024).
- Staff, T. Some 175,000 Israeli Kids Not Immunized Against Polio Virus—Health Ministry. Available online: https://www.timesofisrael.com/some-175000-israeli-kids-not-immunized-against-polio-virus-health-ministry/ (accessed on 28 October 2024).
- Reported Impact Snapshot|Gaza Strip (25 September 2024). Available online: http://www.ochaopt.org/content/reported-impact-snapshot-gaza-strip-25-september-2024 (accessed on 18 October 2024).
- WHO in Lebanon Working to Stop Cholera Spread amid Conflict. Available online: https://www.who.int/news/item/17-10-2024-who-in-lebanon-working-to-stop-cholera-spread-amid-conflict (accessed on 18 October 2024).
- Dattani, S.; Spooner, F.; Ochmann, S.; Roser, M. Our World in Data Polio. Available online: https://ourworldindata.org/polio#all-charts (accessed on 30 September 2024).
- Resolutions of the Geneva International Conference. Geneva. 26–29 October 1863. Available online: https://ihl-databases.icrc.org/en/ihl-treaties/geneva-res-1863 (accessed on 5 November 2024).
- Burki, T. The Illustrious Dead: The Terrifying Story of How Typhus Killed Napoleon’s Greatest Army. Lancet Infect. Dis. 2010, 10, 748. [Google Scholar] [CrossRef]
- Sartin, J.S. Infectious diseases during the Civil War: The triumph of the “Third Army”. Clin. Infect. Dis. 1993, 16, 580–584. [Google Scholar] [CrossRef]
- The Geneva Conventions and Their Commentaries|ICRC. Available online: https://www.icrc.org/en/law-and-policy/geneva-conventions-and-their-commentaries (accessed on 27 October 2024).
- Bashar Al-Assad Is Waging Biological War—By Neglect—Foreign Policy. Available online: https://foreignpolicy.com/2018/10/24/bashar-al-assad-is-waging-biological-war-by-neglect/ (accessed on 27 October 2024).
- Al-Kabbani, I.; Letter to Dr. Tedros Adhanom Ghebreyesus, Director General of the World Health Organization, from the Damascus Director of Health. Available online: https://www.hrw.org/sites/default/files/supporting_resources/syria_eastern_ghouta_doctors.pdf (accessed on 4 November 2024).
- WHO’s Response, and Role As the Health Cluster Lead, in Meeting the Growing Demands of Health in Humanitarian Emergencies World Health Assembly, Resolution 65.20 (2012). Sixty-Fifth World Health Assembly, Geneva. World Health Organization. Available online: https://iris.who.int/bitstream/handle/10665/80494/A65_R20-en.pdf?sequence=1&isAllowed=y (accessed on 29 September 2024).
- World Health Organization. Stopping Attacks on Healthcare. Available online: https://www.who.int/activities/stopping-attacks-on-health-care (accessed on 28 October 2024).
- The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018–2019|New England Journal of Medicine. Available online: https://www.nejm.org/doi/full/10.1056/NEJMsr1904253 (accessed on 24 October 2024).
- Fouad, F.M.; Sparrow, A.; Tarakji, A.; Alameddine, M.; El-Jardali, F.; Coutts, A.P.; Arnaout, N.E.; Karroum, L.B.; Jawad, M.; Roborgh, S.; et al. Health Workers and the Weaponisation of Health Care in Syria: A Preliminary Inquiry for The Lancet–American University of Beirut Commission on Syria. Lancet 2017, 390, 2516–2526. [Google Scholar] [CrossRef]
- WHO Statement on the Meeting of the International Health Regulations Emergency Committee Concerning the International Spread of Wild Poliovirus. Available online: https://www.who.int/news/item/05-05-2014-who-statement-on-the-meeting-of-the-international-health-regulations-emergency-committee-concerning-the-international-spread-of-wild-poliovirus (accessed on 24 October 2024).
- Burki, T. Polio Vaccination Campaign in Gaza. Lancet Infect. Dis. 2024, 24, e623–e624. [Google Scholar] [CrossRef]
- Plans-Rubió, P. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum. Vaccines Immunother. 2012, 8, 184–188. [Google Scholar] [CrossRef]
- Anera. Gaza’s Water Crisis Puts Thousands at Risk of Preventable Death. Available online: https://www.anera.org/blog/gazas-water-crisis-puts-thousands-at-risk-of-preventable-death/ (accessed on 28 October 2024).
- WHO/UNICEF Estimates of National Immunization Coverage WUENIC Trends. Available online: https://worldhealthorg.shinyapps.io/wuenic-trends/ (accessed on 28 October 2024).
- Statement of the Thirty-Ninth Meeting of the Polio IHR Emergency Committee. Available online: https://www.who.int/news/item/13-08-2024-statement-of-the-thirty-ninth-meeting-of-the-polio-ihr-emergency-committee (accessed on 26 September 2024).
- Parker, E.P.K.; Ramani, S.; Lopman, B.A.; Church, J.A.; Iturriza-Gómara, M.; Prendergast, A.J.; Grassly, N.C. Causes of Impaired Oral Vaccine Efficacy in Developing Countries. Future Microbiol. 2017, 13, 97–118. [Google Scholar] [CrossRef]
- Eurosurveillance|An Imported Case of Vaccine-Derived Poliovirus Type 2, Spain in the Context of the Ongoing Polio Public Health Emergency of International Concern. September 2021. Available online: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.50.2101068 (accessed on 24 October 2024).
- Human Rights Watch. DR Congo: Rwandan Forces, M23 Rebels Shell Civilians. Available online: https://www.hrw.org/news/2024/09/26/dr-congo-rwandan-forces-m23-rebels-shell-civilians (accessed on 23 October 2024).
- Ministere de la Sante Publique, Hygiène et Prevoyance Sociale. Rapport Journalier de l’épidémie de Mpox en RDC, Sitrep No. 74, October 2024. Available online: https://reliefweb.int/report/democratic-republic-congo/rapport-journalier-de-lepidemie-de-mpox-en-rdc-sitrep-ndeg74-donnees-du-25-octobre-2024-semaine-epidemiologique-43 (accessed on 4 November 2024).
- Moussally, K.; Abu-Sittah, G.; Gomez, F.G.; Fayad, A.A.; Farra, A. Antimicrobial Resistance in the Ongoing Gaza War: A Silent Threat. Lancet 2023, 402, 1972–1973. [Google Scholar] [CrossRef] [PubMed]
- WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Available online: https://www.who.int/publications/i/item/9789240093461 (accessed on 3 November 2024).
- Castanheira, M.; Mendes, R.E.; Gales, A.C. Global Epidemiology and Mechanisms of Resistance of Acinetobacter Baumannii-Calcoaceticus Complex. Clin. Infect. Dis. 2023, 76, S166–S178. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. 2.2 TB Mortality 2022. Available online: https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=A%20total%20of%201.3%20million,167%20000%20people%20with%20HIV (accessed on 23 October 2024).
- Farhat, M.; Cox, H.; Ghanem, M.; Denkinger, C.M.; Rodrigues, C.; Abd El Aziz, M.S.; Enkh-Amgalan, H.; Vambe, D.; Ugarte-Gil, C.; Furin, J.; et al. Drug-Resistant Tuberculosis: A Persistent Global Health Concern. Nat. Rev. Microbiol. 2024, 22, 617–635. [Google Scholar] [CrossRef]
- Kimbrough, W.; Saliba, V.; Dahab, M.; Haskew, C.; Checchi, F. The Burden of Tuberculosis in Crisis-Affected Populations: A Systematic Review—The Lancet Infectious Diseases. Lancet Infect. Dis. 2012, 12, 950–965. [Google Scholar] [CrossRef]
- United Nations High Commissioner for Refugees. 2022 Ukraine Situation. Available online: https://reporting.unhcr.org/ukraine-situation-global-report-2022 (accessed on 28 October 2024).
- TB among Refugees from Ukraine in European Countries|The Union. Available online: https://theunion.org/news/tb-among-refugees-from-ukraine-in-european-countries (accessed on 18 October 2024).
- Häcker, B.; Breuer, C.; Priwitzer, M.; Otto-Knapp, R.; Bauer, T. TB Screening of Ukrainian Refugees in Germany. Int. J. Tuberc. Lung Dis. 2023, 27, 641. [Google Scholar] [CrossRef]
- Abbara, A.; Almalla, M.; AlMasri, I.; AlKabbani, H.; Karah, N.; El-Amin, W.; Rajan, L.; Rahhal, I.; Alabbas, M.; Sahloul, Z.; et al. The Challenges of Tuberculosis Control in Protracted Conflict: The Case of Syria. Int. J. Infect. Dis. 2020, 90, 53–59. [Google Scholar] [CrossRef]
- Vulnerable Population and TB. Available online: https://www.who.int/teams/global-tuberculosis-programme/populations-comorbidities/vulnerable-population (accessed on 26 September 2024).
- Abbara, A.; AlKabbani, H.; Al-Masri, I.; Sahloul, Z.; Sparrow, A. Populations under Siege and in Prison Require Investment from Syria’s National Tuberculosis Programme. Lancet Respir. Med. 2018, 6, e34. [Google Scholar] [CrossRef]
- Higgins, J.P.T.; Soares-Weiser, K.; López-López, J.A.; Kakourou, A.; Chaplin, K.; Christensen, H.; Martin, N.K.; Sterne, J.A.C.; Reingold, A.L. Association of BCG, DTP, and Measles Containing Vaccines with Childhood Mortality: Systematic Review. BMJ 2016, 355, i5170. [Google Scholar] [CrossRef]
- Biering-Sørensen, S.; Aaby, P.; Lund, N.; Monteiro, I.; Jensen, K.J.; Eriksen, H.B.; Schaltz-Buchholzer, F.; Jørgensen, A.S.P.; Rodrigues, A.; Fisker, A.B.; et al. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial. Clin. Infect. Dis. 2017, 65, 1183–1190. [Google Scholar] [CrossRef]
- Prentice, S.; Nassanga, B.; Webb, E.L.; Akello, F.; Kiwudhu, F.; Akurut, H.; Elliott, A.M.; Arts, R.J.W.; Netea, M.G.; Dockrell, H.M.; et al. BCG-Induced Non-Specific Effects on Heterologous Infectious Disease in Ugandan Neonates: An Investigator-Blind Randomised Controlled Trial. Lancet Infect. Dis. 2021, 21, 993–1003. [Google Scholar] [CrossRef]
- Greenblatt, C.L.; Lathe, R. Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia. J. Alzheimers Dis. 2024, 98, 361–372. [Google Scholar] [CrossRef]
- Kühtreiber, W.M.; Faustman, D.L. BCG Therapy for Type 1 Diabetes: Restoration of Balanced Immunity and Metabolism. Trends Endocrinol. Metab. 2019, 30, 80–92. [Google Scholar] [CrossRef] [PubMed]
- Piedra, P.A.; Gaglani, M.J.; Kozinetz, C.A.; Herschler, G.B.; Fewlass, C.; Harvey, D.; Zimmerman, N.; Glezen, W.P. Trivalent Live Attenuated Intranasal Influenza Vaccine Administered During the 2003–2004 Influenza Type A (H3N2) Outbreak Provided Immediate, Direct, and Indirect Protection in Children. Pediatrics 2007, 120, e553–e564. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.J.; Lee, J.Y.; Jang, Y.H.; Seo, S.-U.; Chang, J.; Seong, B.L. Non-Specific Effect of Vaccines: Immediate Protection Against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. Front. Microbiol. 2018, 9, 83. [Google Scholar] [CrossRef] [PubMed]
- Principi, N.; Esposito, S. Specific and Nonspecific Effects of Influenza Vaccines. Vaccines 2024, 12, 384. [Google Scholar] [CrossRef]
- Sabin, A.B. Characteristics and Genetic Potentialities of Experimentally Produced and Naturally Occurring Variants of Poliomyelitis Virus. Ann. N. Y. Acad. Sci. 1955, 61, 924–939. [Google Scholar] [CrossRef]
- Voroshilova, M.K. Potential Use of Nonpathogenic Enteroviruses for Control of Human Disease. Prog. Med. Virol. 1989, 36, 191–202. [Google Scholar]
- Chumakov, M.P.; Voroshilova, M.K.; Antsupova, A.S.; Boĭko, V.M.; Blinova, M.I.; Priĭmiagi, L.S.; Rodin, V.I.; Seĭbil’, V.B.; Siniak, K.M.; Smorodintsev, A.A. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol. Epidemiol. Immunobiol. 1992, 11–12, 37–40. [Google Scholar]
- Contreras, G. Sabin’s Vaccine Used for Nonspecific Prevention of Infant Diarrhea of Viral Etiology. Bull. Pan. Am. Health Organ. 1974, 8, 123–132. [Google Scholar]
- Andersen, A.; Fisker, A.B.; Rodrigues, A.; Martins, C.; Ravn, H.; Lund, N.; Biering-Sørensen, S.; Benn, C.S.; Aaby, P. National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment Within Seven Randomized Trials. Front. Public Health 2018, 6, 13. [Google Scholar] [CrossRef]
- Andersen, A.; Fisker, A.B.; Nielsen, S.; Rodrigues, A.; Benn, C.S.; Aaby, P. National Immunization Campaigns with Oral Polio Vaccine May Reduce All-Cause Mortality: An Analysis of 13 Years of Demographic Surveillance Data from an Urban African Area. Clin. Infect. Dis. 2021, 72, e596–e603. [Google Scholar] [CrossRef]
- Nielsen, S.; Khalek, M.A.; Benn, C.S.; Aaby, P.; Hanifi, S.M.A. National Immunisation Campaigns with Oral Polio Vaccine May Reduce All-Cause Mortality: Analysis of 2004–2019 Demographic Surveillance Data in Rural Bangladesh. EClinicalMedicine 2021, 36, 100886. [Google Scholar] [CrossRef] [PubMed]
- Lund, N.; Andersen, A.; Hansen, A.S.K.; Jepsen, F.S.; Barbosa, A.; Biering-Sørensen, S.; Rodrigues, A.; Ravn, H.; Aaby, P.; Benn, C.S. The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial. Clin. Infect. Dis. 2015, 61, 1504–1511. [Google Scholar] [CrossRef] [PubMed]
- Alam, M.J.; Rashid, M.M.; Kabir, Y.; Raqib, R.; Ahmad, S.M. On Birth Single Dose Live Attenuated OPV and BCG Vaccination Induces Gut Cathelicidin LL37 Responses at 6 Week of Age: A Natural Experiment. Vaccine 2015, 33, 18–21. [Google Scholar] [CrossRef] [PubMed]
- Jensen, K.J.; Karkov, H.S.; Lund, N.; Andersen, A.; Eriksen, H.B.; Barbosa, A.G.; Kantsø, B.; Aaby, P.; Benn, C.S. The Immunological Effects of Oral Polio Vaccine Provided with BCG Vaccine at Birth: A Randomised Trial. Vaccine 2014, 32, 5949–5956. [Google Scholar] [CrossRef]
- Medeiros, M.M.; Ingham, A.C.; Nanque, L.M.; Correia, C.; Stegger, M.; Andersen, P.S.; Fisker, A.B.; Benn, C.S.; Lanaspa, M.; Silveira, H.; et al. Oral Polio Revaccination Is Associated with Changes in Gut and Upper Respiratory Microbiomes of Infants. Front. Microbiol. 2022, 13, 1016220. [Google Scholar] [CrossRef]
- Kleinnijenhuis, J.; Quintin, J.; Preijers, F.; Joosten, L.A.B.; Ifrim, D.C.; Saeed, S.; Jacobs, C.; van Loenhout, J.; de Jong, D.; Stunnenberg, H.G.; et al. Bacille Calmette-Guerin Induces NOD2-Dependent Nonspecific Protection from Reinfection via Epigenetic Reprogramming of Monocytes. Proc. Natl. Acad. Sci. USA 2012, 109, 17537–17542. [Google Scholar] [CrossRef]
- Arts, R.J.W.; Moorlag, S.J.C.F.M.; Novakovic, B.; Li, Y.; Wang, S.-Y.; Oosting, M.; Kumar, V.; Xavier, R.J.; Wijmenga, C.; Joosten, L.A.B.; et al. BCG Vaccination Protects Against Experimental Viral Infection in Humans Through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe 2018, 23, 89–100.e5. [Google Scholar] [CrossRef]
- Netea, M.G.; Domínguez-Andrés, J.; Barreiro, L.B.; Chavakis, T.; Divangahi, M.; Fuchs, E.; Joosten, L.A.B.; van der Meer, J.W.M.; Mhlanga, M.M.; Mulder, W.J.M.; et al. Defining Trained Immunity and Its Role in Health and Disease. Nat. Rev. Immunol. 2020, 20, 375–388. [Google Scholar] [CrossRef]
- Cirovic, B.; de Bree, L.C.J.; Groh, L.; Blok, B.A.; Chan, J.; van der Velden, W.J.F.M.; Bremmers, M.E.J.; van Crevel, R.; Händler, K.; Picelli, S.; et al. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. Cell Host Microbe 2020, 28, 322–334.e5. [Google Scholar] [CrossRef]
- Koeken, V.A.; de Bree, L.C.J.; Mourits, V.P.; Moorlag, S.J.; Walk, J.; Cirovic, B.; Arts, R.J.; Jaeger, M.; Dijkstra, H.; Lemmers, H.; et al. BCG Vaccination in Humans Inhibits Systemic Inflammation in a Sex-Dependent Manner. J. Clin. Investig. 2020, 130, 5591–5602. [Google Scholar] [CrossRef]
- Röring, R.J.; Debisarun, P.A.; Botey-Bataller, J.; Suen, T.K.; Bulut, Ö.; Kilic, G.; Koeken, V.A.; Sarlea, A.; Bahrar, H.; Dijkstra, H.; et al. MMR Vaccination Induces Trained Immunity via Functional and Metabolic Reprogramming of Γδ T Cells. J. Clin. Investig. 2024, 134, e170848. [Google Scholar] [CrossRef] [PubMed]
- Suen, T.K.; Moorlag, S.J.C.F.M.; Li, W.; de Bree, L.C.J.; Koeken, V.A.C.M.; Mourits, V.P.; Dijkstra, H.; Lemmers, H.; Bhat, J.; Xu, C.-J.; et al. BCG Vaccination Induces Innate Immune Memory in Γδ T Cells in Humans. J. Leukoc. Biol. 2024, 115, 149–163. [Google Scholar] [CrossRef] [PubMed]
- Seppälä, E.; Viskari, H.; Hoppu, S.; Honkanen, H.; Huhtala, H.; Simell, O.; Ilonen, J.; Knip, M.; Hyöty, H. Viral Interference Induced by Live Attenuated Virus Vaccine (OPV) Can Prevent Otitis Media. Vaccine 2011, 29, 8615–8618. [Google Scholar] [CrossRef]
- Upfill-Brown, A.; Taniuchi, M.; Platts-Mills, J.A.; Kirkpatrick, B.; Burgess, S.L.; Oberste, M.S.; Weldon, W.; Houpt, E.; Haque, R.; Zaman, K.; et al. Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants. Clin. Infect. Dis. 2017, 65, 414–419. [Google Scholar] [CrossRef]
- UNICEF Diarrhoea Data. Available online: https://data.unicef.org/topic/child-health/diarrhoeal-disease/ (accessed on 30 September 2024).
- Chumakov, K.; Benn, C.S.; Aaby, P.; Kottilil, S.; Gallo, R. Can Existing Live Vaccines Prevent COVID-19? Science 2020, 368, 1187–1188. [Google Scholar] [CrossRef]
- Yagovkina, N.V.; Zheleznov, L.M.; Subbotina, K.A.; Tsaan, A.A.; Kozlovskaya, L.I.; Gordeychuk, I.V.; Korduban, A.K.; Ivin, Y.Y.; Kovpak, A.A.; Piniaeva, A.N.; et al. Vaccination with Oral Polio Vaccine Reduces COVID-19 Incidence. Front. Immunol. 2022, 13, 907341. [Google Scholar] [CrossRef]
- Fisker, A.B.; Martins, J.S.D.; Nanque, L.M.; Jensen, A.M.; Ca, E.J.C.; Nielsen, S.; Martins, C.L.; Rodrigues, A. Oral Polio Vaccine to Mitigate the Risk of Illness and Mortality During the Coronavirus Disease 2019 Pandemic: A Cluster-Randomized Trial in Guinea-Bissau. Open Forum Infect. Dis. 2022, 9, ofac470. [Google Scholar] [CrossRef]
- Giamarellos-Bourboulis, E.J.; Tsilika, M.; Moorlag, S.; Antonakos, N.; Kotsaki, A.; Domínguez-Andrés, J.; Kyriazopoulou, E.; Gkavogianni, T.; Adami, M.-E.; Damoraki, G.; et al. Activate: Randomized Clinical Trial of BCG Vaccination Against Infection in the Elderly. Cell 2020, 183, 315–323.e9. [Google Scholar] [CrossRef]
- Tsilika, M.; Taks, E.; Dolianitis, K.; Kotsaki, A.; Leventogiannis, K.; Damoulari, C.; Kostoula, M.; Paneta, M.; Adamis, G.; Papanikolaou, I.; et al. ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk. Front. Immunol. 2022, 13, 873067. [Google Scholar] [CrossRef]
- Faustman, D.L.; Lee, A.; Hostetter, E.R.; Aristarkhova, A.; Ng, N.C.; Shpilsky, G.F.; Tran, L.; Wolfe, G.; Takahashi, H.; Dias, H.F.; et al. Multiple BCG Vaccinations for the Prevention of COVID-19 and Other Infectious Diseases in Type 1 Diabetes. Cell Rep. Med. 2022, 3, 100728. [Google Scholar] [CrossRef]
- Koekenbier, E.L.; Fohse, K.; van de Maat, J.S.; Oosterheert, J.J.; van Nieuwkoop, C.; Hoogerwerf, J.J.; Grobusch, M.P.; van den Bosch, M.A.A.J.; van de Wijgert, J.H.H.; Netea, M.G.; et al. Bacillus Calmette-Guérin Vaccine for Prevention of COVID-19 and Other Respiratory Tract Infections in Older Adults with Comorbidities: A Randomized Controlled Trial. Clin. Microbiol. Infect. 2023, 29, 781–788. [Google Scholar] [CrossRef] [PubMed]
- Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/35247264/ (accessed on 30 September 2024).
- Madsen, A.M.R.; Schaltz-Buchholzer, F.; Nielsen, S.; Benfield, T.; Bjerregaard-Andersen, M.; Dalgaard, L.S.; Dam, C.; Ditlev, S.B.; Faizi, G.; Azizi, M.; et al. Using BCG Vaccine to Enhance Nonspecific Protection of Health Care Workers During the COVID-19 Pandemic: A Randomized Controlled Trial. J. Infect. Dis. 2024, 229, 384–393. [Google Scholar] [CrossRef]
- Debisarun, P.A.; Kilic, G.; de Bree, L.C.J.; Pennings, L.J.; van Ingen, J.; Benn, C.S.; Aaby, P.; Dijkstra, H.; Lemmers, H.; Domínguez-Andrés, J.; et al. The Impact of BCG Dose and Revaccination on Trained Immunity. Clin. Immunol. 2023, 246, 109208. [Google Scholar] [CrossRef] [PubMed]
- Schaltz-Buchholzer, F.; Biering-Sørensen, S.; Lund, N.; Monteiro, I.; Umbasse, P.; Fisker, A.B.; Andersen, A.; Rodrigues, A.; Aaby, P.; Benn, C.S. Early BCG Vaccination, Hospitalizations, and Hospital Deaths: Analysis of a Secondary Outcome in 3 Randomized Trials from Guinea-Bissau. J. Infect. Dis. 2019, 219, 624–632. [Google Scholar] [CrossRef]
- Benn, C.S.; Fisker, A.B.; Whittle, H.C.; Aaby, P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. EBioMedicine 2016, 10, 312–317. [Google Scholar] [CrossRef]
- Aaby, P.; Netea, M.G.; Benn, C.S. Beneficial Non-Specific Effects of Live Vaccines Against COVID-19 and Other Unrelated Infections. Lancet Infect. Dis. 2023, 23, e34–e42. [Google Scholar] [CrossRef]
- Benn, C.S.; Netea, M.G.; Aaby, P. BCG to Protect Against COVID-19 in Health Care Workers. N. Engl. J. Med. 2023, 389, 191–192. [Google Scholar] [CrossRef]
- Fedrizzi, E.N.; Girondi, J.B.R.; Sakae, T.M.; Steffens, S.M.; Silvestrin, A.N.D.S.; Claro, G.S.; Iskenderian, H.A.; Hillmann, B.; Gervasi, L.; Trapani, A.; et al. Efficacy of the Measles-Mumps-Rubella (Mmr) Vaccine in the Reducing the Severity of COVID-19: An Interim Analysis of a Randomised Controlled Clinical Trial. medRxiv 2021. [Google Scholar] [CrossRef]
- History of Polio Vaccination. Available online: https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-polio-vaccination (accessed on 28 October 2024).
- Districts of Pakistan Boycott Polio Immunisation until Economic and Health Demands Are Met|The BMJ. Available online: https://www.bmj.com/content/383/bmj.p2890 (accessed on 26 September 2024).
- Jegede, A.S. What Led to the Nigerian Boycott of the Polio Vaccination Campaign? PLoS Med. 2007, 4, e73. [Google Scholar] [CrossRef]
- Fake CIA Vaccine Campaign: When the End Doesn’t Justify the Means|Smart Global Health|CSIS. Available online: https://www.csis.org/blogs/smart-global-health/fake-cia-vaccine-campaign-when-end-doesnt-justify-means (accessed on 24 October 2024).
- Pentagon Ran Secret Anti-Vax Campaign to Incite Fear of China Vaccines. Reuters. Available online: https://www.reuters.com/investigates/special-report/usa-covid-propaganda/ (accessed on 30 September 2024).
- World Trade Organization|Intellectual Property—Overview of TRIPS Agreement 1994. Available online: https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm (accessed on 30 September 2024).
- Hood, C.M.; Gennuso, K.P.; Swain, G.R.; Catlin, B.B. County Health Rankings: Relationships Between Determinant Factors and Health Outcomes. Am. J. Prev. Med. 2016, 50, 129–135. [Google Scholar] [CrossRef]
- Mangione, S.; Tykocinski, M.L. Virchow at 200 and Lown at 100—Physicians as Activists. N. Engl. J. Med. 2021, 385, 291–293. [Google Scholar] [CrossRef]
- Schultz, M. Rudolf Virchow. Emerg. Infect. Dis. 2008, 14, 1480. [Google Scholar] [CrossRef]
- Rieckmann, A.; Villumsen, M.; Sørup, S.; Haugaard, L.K.; Ravn, H.; Roth, A.; Baker, J.L.; Benn, C.S.; Aaby, P. Vaccinations against Smallpox and Tuberculosis Are Associated with Better Long-Term Survival: A Danish Case-Cohort Study 1971–2010. Int. J. Epidemiol. 2017, 46, 695–705. [Google Scholar] [CrossRef] [PubMed]
- Children at Severe Risk of Death from Mpox, World Vision Warns|World Vision. Available online: https://www.worldvision.org/about-us/media-center/children-at-severe-risk-of-death-from-mpox-world-vision-warns (accessed on 30 September 2024).
- WHO Director-General Declares Mpox Outbreak a Public Health Emergency of International Concern. Available online: https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern (accessed on 28 October 2024).
- Jensen, M.L.; Dave, S.; Schim van der Loeff, M.; da Costa, C.; Vincent, T.; Leligdowicz, A.; Benn, C.S.; Roth, A.; Ravn, H.; Lisse, I.M.; et al. Vaccinia Scars Associated with Improved Survival Among Adults in Rural Guinea-Bissau. PLoS ONE 2006, 1, e101. [Google Scholar] [CrossRef]
- Sørup, S.; Villumsen, M.; Ravn, H.; Benn, C.S.; Sørensen, T.I.A.; Aaby, P.; Jess, T.; Roth, A. Smallpox Vaccination and All-Cause Infectious Disease Hospitalization: A Danish Register-Based Cohort Study. Int. J. Epidemiol. 2011, 40, 955–963. [Google Scholar] [CrossRef]
- Rieckmann, A.; Villumsen, M.; Jensen, M.L.; Ravn, H.; da Silva, Z.J.; Sørup, S.; Baker, J.L.; Rodrigues, A.; Benn, C.S.; Roth, A.E.; et al. The Effect of Smallpox and Bacillus Calmette-Guérin Vaccination on the Risk of Human Immunodeficiency Virus-1 Infection in Guinea-Bissau and Denmark. Open Forum Infect. Dis. 2017, 4, ofx130. [Google Scholar] [CrossRef]
- Rieckmann, A.; Villumsen, M.; Hønge, B.L.; Sørup, S.; Rodrigues, A.; da Silva, Z.J.; Whittle, H.; Benn, C.; Aaby, P. Phase-out of Smallpox Vaccination and the Female/Male HIV-1 Prevalence Ratio: An Ecological Study from Guinea-Bissau. BMJ Open 2019, 9, e031415. [Google Scholar] [CrossRef]
- Weinstein, R.S.; Weinstein, M.M.; Alibek, K.; Bukrinsky, M.I.; Brichacek, B. Significantly Reduced CCR5-Tropic HIV-1 Replication in Vitro in Cells from Subjects Previously Immunized with Vaccinia Virus. BMC Immunol. 2010, 11, 23. [Google Scholar] [CrossRef]
- Aaby, P.; Benn, C.S. Stopping Live Vaccines after Disease Eradication May Increase Mortality. Vaccine 2020, 38, 10–14. [Google Scholar] [CrossRef]
- Population with Household Expenditures on Health Greater than 25% of Total Household Expenditure or Income (SDG Indicator 3.8.2) (%, National, Rural, Urban). Available online: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/population-with-household-expenditures-on-health-greater-than-25-of-total-household-expenditure-or-income-(-sdg-indicator-3-8-2)-(-) (accessed on 28 October 2024).
Variola (Orthopoxvirus) | Polio (Enterovirus) | |
---|---|---|
Membrane | Enveloped | Naked |
Size | 302–350 nm by 244–270 nm | 6–30 nm |
Mode of Transmission | Airborne | Fecal-Oral Waterborne Airborne Fomites |
Clinical Surveillance | Sensitive | Multiple causes of AFP |
Viral Reservoirs | Human | Human Water Sewage Soil |
Diagnosis | Clinical | Laboratory confirmation |
Susceptible to Handwashing | No | Yes |
Vaccination Strategy | Ring Vaccination | Herd immunity |
Sterilizing Immunity | Yes | No |
Number of Vaccinations | Single | Multiple |
Strains/Serotypes and Vaccine cross reactivity | Variola major, V. minor, with cross-reactivity | Three serotypes, 1, 2, 3 no cross-reactivity |
Source | Wild Virus Type 1 Confirmed Cases | Wild Virus Type 1 Reported from Environmental Samples, Selected Contacts, Healthy Children, and Other Sources | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period | Full Year Total | 01-Jan–12-Nov ¹ | Date of Most Recent Virus | Full Year Total | 01-Jan–12-Nov ¹ | Date of Most Recent Virus | |||||||||||
Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
Afghanistan | 21 | 29 | 56 | 4 | 2 | 6 | 6 | 23 | 14-Sep-24 | 86 | 66 | 43 | 1 | 22 | 62 | 100 | 23-Sep-24 |
Pakistan | 12 | 147 | 84 | 1 | 20 | 6 | 5 | 48 | 25-Oct-24 | 139 | 391 | 438 | 65 | 41 | 127 | 514 | 22-Oct-24 |
Islamic Republic of Iran | 3 | 20-May-19 | |||||||||||||||
Malawi | 1 | 19-Nov21 | |||||||||||||||
Mozambique | 8 | 10-Aug22 | |||||||||||||||
TOTAL (TYPE 1) | 33 | 176 | 140 | 6 | 30 | 12 | 11 | 71 | 225 | 460 | 481 | 66 | 63 | 189 | 614 | ||
Tot. in endemic countries | 33 | 176 | 140 | 5 | 22 | 12 | 11 | 71 | 225 | 457 | 481 | 66 | 63 | 189 | 614 | ||
Tot. in non-end countries | 1 | 8 | 3 | ||||||||||||||
No. of countries (infected) | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | |||||
No. of countries (endemic) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Total Female | 18 | 72 | 59 | 2 | 10 | 4 | 2 | 3 | 1 | ||||||||
Total Male | 15 | 104 | 81 | 4 | 20 | 8 | 8 |
Top 15 Countries with Greatest % IDPs | Country/Territory Where Polio Outbreak Occurred | Total Estimated Population, Millions | Internally Displaced Persons (IPDs), Millions | Percent of Population Internally Displaced | Year of Onset of Polio Outbreak |
---|---|---|---|---|---|
1 | Gaza | 2.1 M | 1.87 M | 85% | 2024 |
2 | Syrian Arab Republic | 23.5 M | 7.25 M | 31.0% | 2013, 2017 |
3 | Somalia | 18.7 M | 3.9 M | 20.9% | 2017 |
4 | Sudan | 49.4 M | 9.1 M | 18.4% | 2020, 2022 |
5 | South Sudan | 11.3 M | 2 M | 17.7% | 2020 |
6 | Yemen | 35.2 M | 4.52 M | 12.8% | 2020, 2021 |
7 | Ukraine | 37.9 M | 3.67 M | 9.7% | 2021 |
8 | Afghanistan | 43.4 M | 4.2 M | 9.7% | 2017 |
9 | Burkina Faso | 22.7 M | 2.1 M | 9.3% | 2020 |
10 | Central African Republic | 6.1 M | 0.45 M | 7.4% | 2019 |
11 | Democratic Republic of the Congo | 113.6 M | 7.3 M | 6.4% | 2017 |
12 | Cameroon | 29.4 M | 1.04 M | 3.5% | 2019 |
13 | Ethiopia | 126.5 M | 4.38 M | 3.5% | 2013, 2020 |
14 | Iraq | 46.5 M | 1.3 M | 2.8% | 2013 |
15 | Mozambique | 32.9 M | 0.72 M | 2.2% | 2021, 2022 |
Setting, Year | Examples |
---|---|
Afghanistan, 2023 [8] | In September 2023, all 5 children paralyzed by poliomyelitis had been vaccinated, between 16 and 28 times each. |
India, 1969–1976 [42] | In northern India, seroconversion after 1 dose of trivalent OPV (tOPV) was less than 10%. There was interference between serotypes of Sabin strains and the presence of other microbes causing gastro-enteritic infection, particularly enteroviruses. Therefore, it took repeated vaccination—up to 50 doses of tOPV—to reach a level of population immunity sufficient to stop transmission of WPV1. |
Spain, 2021 [43] | In September 2021, a case of cVDPV2 was detected in a 6-year-old child in Murcia, Spain. The child arrived from Senegal in August 2021, and the child’s vaccination record showed that 4 doses of OPV and 1 dose of IPV had been administered during their first year of life. |
|
Setting | Examples |
---|---|
Ukraine | Ukraine has a chronically high burden of DR-TB. Globally, it has the fifth-highest number of confirmed cases of extremely drug-resistant TB (XDR-TB). The systematic assault on healthcare—destroying 400 health facilities, including three TB hospitals—in combination with indiscriminate bombing of civilians, created more than 5 million refugees during the first few months after Russia’s invasion, and nearly 6 million more internal displacements [52]. Because everyone has the need for healthcare, the deliberate targeting of hospitals is a primary driver of displacement and deploys people’s need for healthcare against them. This fueled the spread of DR-TB to several European countries such as Germany, France, Poland, Czechia, Estonia, Moldova, and Lithuania [53]. Germany anticipated the threat and set up screening programs for Ukrainian refugees [54]. Other countries, such as Poland, are ill-equipped to screen and treat refugees. |
Syria | Pre-conflict, incidence of TB in Syria was officially reported at 22 per 100,000 persons. Beginning in March 2011, systematic violations of humanitarian law decimated the healthcare system, destroyed key infrastructure, displaced more than 60% of the population, and detained more than 100,000 people. The attrition of healthcare specialists was driven by killings, arrests, and flight. This created ideal conditions for the transmission of TB and the cultivation of drug-resistant strains, while restricting the ability to diagnose, trace contacts, treat, and follow up. Limited diagnostics affected the diagnosis of multidrug- (MDR-TB) and rifampicin-resistant TB (RR-TB), which reportedly comprised 8.8% of all new diagnoses in 2017. The official figure for 2017 of 19 per 100,000 is likely a vast underestimation, given the challenges and barriers to case detection. UN humanitarian convoys were not permitted to deliver TB treatment or vaccines to populations under siege, nor to evacuate critically ill patients. In 2017, three children died in besieged Eastern Ghouta. In northwest Syria, the last enclave of opposition territory, the incidence of TB was estimated at 72 per 100,000. DR-TB also spread into neighboring countries that were receiving Syrian refugees [55]. |
Incarcerated populations | According to WHO, the prevalence of TB in prisons is estimated to be up to 100 times higher than in civilian populations [56]. Being incarcerated greatly increases the risk of contracting TB, including DR-TB, due to harsh conditions such as overcrowding and malnutrition. International policies and programs often ignore prison populations, with the result that TB is under-diagnosed, and prisoners lack access to treatment. In places where anti-TB medications are available to the incarcerated, treatment regimens are often inconsistent, interrupted or incomplete, further increasing the risk of developing DR-TB. This has led to high levels of DR-TB being reported in prisons worldwide, with some prisons reporting that up to 24% of TB cases are DR-TB strains [56]. Without treatment and under conditions of incarceration, TB progresses rapidly. In Syria in 2013, TB was reported to be a leading cause of death in Aleppo Central Prison, responsible for 25% of the 400 deaths in the prison between April 2012 and October 2013 [57]. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sparrow, A.; Smith-Torino, M.; Shamamba, S.M.; Chirakarhula, B.; Lwaboshi, M.A.; Benn, C.S.; Chumakov, K. A Risk Management Approach to Global Pandemics of Infectious Disease and Anti-Microbial Resistance. Trop. Med. Infect. Dis. 2024, 9, 280. https://doi.org/10.3390/tropicalmed9110280
Sparrow A, Smith-Torino M, Shamamba SM, Chirakarhula B, Lwaboshi MA, Benn CS, Chumakov K. A Risk Management Approach to Global Pandemics of Infectious Disease and Anti-Microbial Resistance. Tropical Medicine and Infectious Disease. 2024; 9(11):280. https://doi.org/10.3390/tropicalmed9110280
Chicago/Turabian StyleSparrow, Annie, Meghan Smith-Torino, Samuel M. Shamamba, Bisimwa Chirakarhula, Maranatha A. Lwaboshi, Christine Stabell Benn, and Konstantin Chumakov. 2024. "A Risk Management Approach to Global Pandemics of Infectious Disease and Anti-Microbial Resistance" Tropical Medicine and Infectious Disease 9, no. 11: 280. https://doi.org/10.3390/tropicalmed9110280
APA StyleSparrow, A., Smith-Torino, M., Shamamba, S. M., Chirakarhula, B., Lwaboshi, M. A., Benn, C. S., & Chumakov, K. (2024). A Risk Management Approach to Global Pandemics of Infectious Disease and Anti-Microbial Resistance. Tropical Medicine and Infectious Disease, 9(11), 280. https://doi.org/10.3390/tropicalmed9110280